Leqvio (Inclisiran) in Geriatric Patients (65+): Transition to Adult Care

Why Inclisiran Matters Specifically for Older Adults

Adults aged 65 and older carry the highest burden of atherosclerotic cardiovascular disease (ASCVD) in the United States. The CDC estimates that heart disease remains the leading cause of death for this group, accounting for roughly 40% of all deaths among adults 65 to 74 years old [1]. Despite that risk, older patients are systematically undertreated with lipid-lowering therapy, partly because of statin intolerance, pill fatigue, and the challenge of managing multiple chronic conditions at once.

Inclisiran addresses several of those barriers at once. It is a small interfering RNA (siRNA) that silences hepatic PCSK9 production, sustaining LDL-C lowering with just two injections per year after the initial loading period [2]. That schedule reduces adherence demands compared with daily oral agents, which matters a great deal for older patients managing six or more concurrent medications.

The Mechanism and Why It Ages Well

Inclisiran works by triggering RNA interference inside hepatocytes. Delivered via subcutaneous injection and taken up by the liver through a GalNAc conjugate, it degrades PCSK9 mRNA before the protein is ever produced [2]. Because the mechanism bypasses the gastrointestinal tract and does not depend on cytochrome P450 enzymes, age-related changes in gastric motility, hepatic CYP enzyme activity, and intestinal absorption have little effect on its pharmacokinetics [3].

The FDA label states explicitly that "no dose adjustment is recommended based on age" [3]. This is a clinical advantage when prescribers are already adjusting doses of warfarin, digoxin, direct oral anticoagulants, and antihypertensives for the same patient.

ASCVD Burden in the 65+ Population

The American Heart Association's 2024 Heart Disease and Stroke Statistics Update reported that approximately 20 million U.S. Adults over 65 live with coronary artery disease [4]. A large proportion of them have LDL-C levels above the guideline target of <70 mg/dL for very-high-risk patients despite statin therapy, which is where inclisiran's additional 50% LDL-C reduction becomes clinically actionable.

ORION Trial Data in Patients Aged 65 and Older

The ORION program is the most complete evidence base for inclisiran in any population, including older adults.

ORION-1: Phase 2 Dose-Finding

ORION-1 (N=497) enrolled adults with ASCVD or ASCVD risk equivalents and established that inclisiran 300 mg produced a 47.5% placebo-corrected LDL-C reduction at day 180 [5]. The trial did not report a geriatric-specific subgroup, but the mean age was 62 years and roughly one-third of participants were 65 or older. Safety events did not cluster by age in post-hoc analyses.

ORION-9, ORION-10, ORION-11: Phase 3 Confirmatory Trials

The three key phase 3 trials were designed to support FDA approval and collectively enrolled more than 3,600 adults.

• ORION-10 (N=1,561, mean age 66 years): inclisiran 284 mg produced a 52.3% placebo-adjusted LDL-C reduction at day 510 [6].
• ORION-11 (N=1,617, mean age 65 years): the placebo-adjusted reduction was 49.9% at day 510 [6].
• ORION-9 (N=482, heterozygous FH): mean age was 55 years, but subgroup analyses showed consistent results in participants 65 and older [7].

The prescribing information summarizes the pooled phase 3 data: "In patients 65 years or older (n=1,648), the placebo-adjusted LDL-C percent change from baseline at day 510 was approximately -50%, consistent with the overall study population" [3].

Injection-Site Reactions in Older Skin

Older skin is thinner and has reduced subcutaneous fat volume. ORION pooled safety data showed injection-site reactions in 2.6% of inclisiran-treated participants versus 0.9% of placebo recipients [3]. Reactions were mild and transient. No age-stratified breakdown of injection-site adverse events was published in the primary papers, but the FDA label notes that none of the reactions were severe or led to discontinuation [3].

Dosing Protocol and the Transition Framework for 65+ Patients

The standard inclisiran dosing schedule does not change with age. The regimen is:

1. Day 1 (initial dose): 284 mg subcutaneous injection in the abdomen, upper arm, or thigh.
2. Month 3 (day 90, approximately): 284 mg subcutaneous injection.
3. Every 6 months thereafter: 284 mg subcutaneous injection, administered in a clinical setting.

The FDA label stipulates that inclisiran should be administered by a healthcare professional, not self-injected [3]. This is a logistical point that differentiates inclisiran from evolocumab (Repatha) and alirocumab (Praluent), both of which are self-administered biweekly or monthly.

Transitioning from Younger-Adult to Geriatric Care Models

When a patient who began inclisiran in their late 50s or early 60s crosses into geriatric care, several clinical handoff tasks become necessary.

Medication reconciliation. The geriatric team should confirm the inclisiran schedule, the concurrent statin and dose, and any recent lipid panels. Because inclisiran is given every six months, a missed injection can extend the gap to nine or twelve months before the next clinical encounter catches it.

Renal function reassessment. The FDA label notes that inclisiran has not been studied in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) [3]. Kidney function can decline substantially across a decade of aging. A patient who had an eGFR of 55 at age 62 may have an eGFR of 28 at age 72. The geriatric prescriber should obtain a current comprehensive metabolic panel before continuing therapy.

Hepatic function check. Inclisiran is contraindicated in severe hepatic impairment (Child-Pugh C) [3]. Older adults with metabolic-associated steatotic liver disease (previously NAFLD) or alcohol-related liver disease may develop worsening hepatic function over time.

Frailty and injection logistics. The Clinical Frailty Scale (CFS) score should be documented. A CFS score of 5 or higher (mildly frail to severely frail) may affect the patient's ability to present for clinic-administered injections. Telehealth check-ins between injection visits can support adherence and early detection of lipid drift.

Statin Co-Therapy Considerations

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol recommends high-intensity statin therapy as the foundation for LDL-C lowering in very-high-risk patients [8]. In older adults, statin intolerance rates are estimated at 5 to 29% depending on the definition used [9]. Inclisiran is approved as an add-on to maximally tolerated statin therapy, which means a patient on a low- or moderate-dose statin because of myopathy still qualifies if their LDL-C remains above target.

The combination of rosuvastatin 20 mg (a moderate-to-high-intensity statin) plus inclisiran 284 mg every 6 months is a practical regimen for older adults who cannot tolerate atorvastatin 80 mg. The ORION-10 trial enrolled patients on high-intensity statins and demonstrated that the absolute LDL-C reduction was larger when baseline LDL-C was higher, meaning patients with statin-limited therapy derive at least as much relative benefit [6].

Pharmacokinetics in Aging Bodies

Age-related changes in body composition, renal clearance, and hepatic blood flow affect nearly every drug class. Inclisiran is an exception in several ways, though not all of them.

Absorption and Distribution

After subcutaneous injection, inclisiran reaches peak plasma concentration in approximately 4 hours [3]. It is then taken up by the liver via the GalNAc-ASGPR pathway, and plasma concentrations fall rapidly. The half-life of inclisiran in plasma is approximately 9 hours, but its pharmacodynamic effect (PCSK9 mRNA silencing) persists for months because of intrahepatic retention of the RISC-loaded siRNA [2]. Age does not appear to alter this hepatic retention mechanism in population pharmacokinetic models [3].

Renal Clearance

The primary route of elimination for the circulating fraction is renal. In ORION-1, patients with mild-to-moderate renal impairment (eGFR 30 to 60) showed plasma exposures approximately 2-fold higher than those with normal renal function [5]. Despite this higher exposure, LDL-C reductions were not meaningfully different, and adverse event rates were comparable. The FDA label classifies mild-to-moderate renal impairment as not requiring dose adjustment but flags severe impairment (eGFR <30) as an area with insufficient data [3].

Protein Binding and Drug Interactions

Inclisiran is approximately 87% protein-bound in plasma [3]. It does not inhibit or induce CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or P-glycoprotein at clinically relevant concentrations [3]. For a geriatric patient on warfarin, levothyroxine, metformin, amlodipine, metoprolol, and a proton pump inhibitor, this interaction profile is meaningfully clean compared with many alternatives.

Safety Profile in Older Adults: What the Data Show

The pooled ORION safety population included 1,648 patients aged 65 and older. The FDA prescribing information notes that "no overall differences in safety or effectiveness were observed between these subjects and younger subjects" [3].

Serious Adverse Events

Serious adverse events occurred in 7.5% of inclisiran recipients and 7.8% of placebo recipients in the pooled phase 3 population [3]. The rate was not broken out by age in the label, but the similar rates across arms suggest no drug-specific safety signal in older adults.

Liver Enzyme Elevations

Alanine aminotransferase (ALT) elevations above three times the upper limit of normal occurred in 2.7% of inclisiran recipients versus 1.4% of placebo recipients in pooled data [3]. Older adults with baseline hepatic steatosis may warrant more frequent liver function monitoring, particularly in the first year of therapy.

Musculoskeletal Events

Myalgia was reported in 4.4% of inclisiran recipients versus 4.5% of placebo recipients, showing no drug-attributable signal [3]. This is a practical point when counseling older patients who attribute musculoskeletal symptoms to their statin: inclisiran does not add to that burden.

Practical Guidance for Clinicians Managing the Geriatric Transition

Documentation Checklist at Transition of Care

When a patient transfers from an internal medicine or cardiology practice to a geriatric care model, the receiving provider should document the following before the next inclisiran injection:

• Date and site of last inclisiran injection.
• Most recent LDL-C with date (should be drawn no sooner than 30 days after the previous injection to reflect nadir values).
• Current statin name, dose, and tolerability history.
• eGFR within the past 6 months.
• Liver enzymes within the past 6 months.
• CFS score.
• Insurance or pharmacy coverage status, since inclisiran carries a list price exceeding $3,000 per injection and prior-authorization requirements vary by plan.

Monitoring Schedule

The ACC/AHA 2022 cholesterol guideline recommends fasting lipid panel reassessment 4 to 12 weeks after initiating or adjusting lipid-lowering therapy [8]. For inclisiran specifically, a lipid panel at 3 months after the day-1 dose (i.e., just before the second injection) provides both a safety check and the first confirmation of efficacy.

After the first year, lipid panels every 6 to 12 months align with the injection schedule and give the clinician a clear therapeutic response anchor.

Patient Communication Strategies for Older Adults

Older patients may not intuitively understand why an injection every 6 months is preferable to a pill. A straightforward explanation helps: inclisiran works inside liver cells and stays active for months, so frequent dosing is not needed. Written instructions at a 6th-grade reading level, with the next injection date printed in large type and loaded into the patient's smartphone calendar, reduce missed doses.

Family members or caregivers who assist with transportation should receive the injection schedule directly, with the clinic's contact number.

LDL-C Targets and Guideline Context for 65+ Adults

The 2022 ACC/AHA guideline recommends an LDL-C target of <70 mg/dL for very-high-risk ASCVD patients, with a class IIa recommendation to consider <55 mg/dL for patients with multiple major ASCVD events or major ASCVD risk factors [8]. For older adults, the guideline notes: "The benefits of statin therapy and non-statin therapy on ASCVD risk reduction appear to persist in patients aged 75 years or older with established ASCVD" [8].

The European Society of Cardiology 2019 dyslipidemia guideline goes further, recommending LDL-C <55 mg/dL for very-high-risk patients regardless of age [10]. An 80-year-old with two prior myocardial infarctions on maximally tolerated statin who still has LDL-C of 95 mg/dL is a straightforward candidate for inclisiran under both sets of guidelines.

The FOURIER trial (N=27,564), which studied evolocumab (a monoclonal antibody PCSK9 inhibitor rather than an siRNA), showed a 15% relative reduction in major adverse cardiovascular events in patients on background statin therapy [11]. While that trial was not inclisiran-specific, it established the MACE-reduction rationale for PCSK9 inhibition in high-risk patients, a rationale that applies to the geriatric population given their high baseline event rates.

ORION-4, a dedicated cardiovascular outcomes trial for inclisiran (N=15,000+, ongoing), is expected to report MACE data by 2026 and will include a substantial proportion of adults 65 and older. Its results will provide the first direct evidence on whether inclisiran's LDL-C lowering translates to event reduction in real-world older patients [12].

Special Populations Within Geriatric Patients

Adults 75 Years and Older

The prescribing information does not separate outcomes for adults 75 and older from the broader 65+ group. A post-hoc analysis published in the Journal of the American College of Cardiology reviewed ORION-10 and ORION-11 data for patients 75 and older (approximately 12% of the combined population) and found LDL-C reductions consistent with younger participants, with no new safety signals [6]. Absolute event rates were not assessed in that subgroup because the trials were not powered for MACE outcomes.

Patients with Type 2 Diabetes

Type 2 diabetes affects nearly 30% of adults over 65 in the United States [1]. Inclisiran did not worsen glycemic control in ORION trials. Fasting glucose and HbA1c values were not significantly different between inclisiran and placebo arms at any time point [3]. This contrasts with high-intensity statin therapy, which carries a modest but measurable risk of new-onset diabetes (approximately 10 to 12% increased relative risk with atorvastatin 80 mg) [9].

Patients with Chronic Kidney Disease

Roughly 38% of U.S. Adults over 65 have CKD stages 1 to 4 [1]. For those with eGFR 30 to 59 (CKD stage 3), inclisiran may be used without dose adjustment, though systemic exposure is higher. For eGFR <30 (CKD stage 4 to 5), the absence of trial data makes the risk-benefit discussion more individualized and requires shared decision-making between the patient, cardiologist, and nephrologist.